切除不能または転移性胃癌または胃食道接合部腺癌患者における皮下注射によるティスレリズマブ投与と静脈内注入および化学療法の併用投与を比較する試験

基本情報

NCT ID

NCT07043400

ステータス

募集中

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

351

治験依頼者名

BeOne Medicines

概要

This study is designed to assess the levels of drug exposure following treatment with tislelizumab administered as a subcutaneous (SC) injection compared to intravenous infusion (IV) as first-line therapy in adults with gastric or gastroesophageal junction (GEJ) that is locally advanced and cannot be surgically removed or has spread from the stomach to other areas of the body. Approximately 351 patients will be participating in this study. The study is composed of a screening period, a treatment period, and a follow-up period.

対象疾患

介入

依頼者（Sponsor）

実施施設 (8)